1227 related articles for article (PubMed ID: 19235559)
1. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
3. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
7. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
8. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
9. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
10. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
11. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
14. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
Recio FO; Piver MS; Hempling RE; Driscoll DL
Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
[TBL] [Abstract][Full Text] [Related]
15. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
16. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients.
Malmström H; Simonsen E; Westberg R
Gynecol Oncol; 1994 Jan; 52(1):20-5. PubMed ID: 8307496
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
19. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
